Combination treatment with MA and osimertinib improved the sensitivity of lung cancer cells to EGFR-TKIs through ROS suppression of the KRAS-ERK signaling pathway, as well as NRF2-SLC7A11 axis inhibition- and mitochondrial Ca2+ overload-triggered ferroptosis. The gene discussed is NFE2L2; the disease is lung cancer.